KX2-361
CAS No. : 897016-26-1
(Synonyms: KX-02)
| Size | Price | Stock |
|---|---|---|
| 5mg | $215 | In-stock |
| 10mg | $355 | In-stock |
| 25mg | $700 | In-stock |
| 50mg | $1050 | In-stock |
| 100mg | $1470 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-111187 |
| M.Wt: | 405.46 |
| Formula: | C24H24FN3O2 |
| Purity: | >98 % |
| Solubility: | DMSO : 10.71 mg/mL (ultrasonic;warming;heat to 60°C) |
KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell[1].
In Vitro: KX2-361 (0-200 nM, 24-72 h) reduces autophosphorylation of Src in GL261 cells[1].
KX2-361 (0-270 nM) promotes cell cycle arrest at the G2/M phase in U87 cells. Note the dose dependent effect and virtual complete arrest at 270 nM[1].
KX2-361 (0-800 nM) induces apoptosis of U87, GL261 and T98G cell lines[1].
KX2-361 (5 µM) inhibits the in vitro assembly of tubulin polymers[1].
In Vivo: KX2‑361 significantly delays progression of orthotopic GL261 brain tumors and produces long‑term survival[1].
KX2-361 demonstrates appreciable brain penetration when dosed orally to mice (20 mg/kg), with a brain Cmax of 4025±319 ng/g observed 15 min post-dosing and an overall exposure (AUClast) of 5044±355 h ng/g[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- KX2-361
- Cat. No.:
- HY-111187
- Quantity:
Your information is safe with us.